RETRACTED ARTICLE:Diagnostic and prognostic value of circulating miR-18a in the plasma of patients with gastric cancer

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12119-12125

  Su, Zhong Xue ^a   Zhao, Juan ^a   Rong, Zhong Hou ^a   Wu, Ya Guang ^a   Geng, Wen Mao ^a   Qin, Cheng Kun ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Biomarker; Gastric cancer; mir 18a; Prognosis

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 18A; UNCLASSIFIED DRUG; MIRN18 MICRORNA, HUMAN; TUMOR MARKER;

AGE DISTRIBUTION; AGED; ARTICLE; BLADDER CANCER; BLOOD LEVEL; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DISEASE MARKER; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA EXTRACTION; SEX DIFFERENCE; STOMACH ADENOCARCINOMA; UPREGULATION; VENOUS BLOOD; BLOOD; CASE CONTROL STUDY; GENETICS; LYMPH NODE METASTASIS; MIDDLE AGED; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; STOMACH NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; ROC CURVE; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84925284811     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2516-6     Document Type: TB

References (32)

1. Fang N, Zhang HQ, He B, Xie M, Lu S, Wan YY, et al. Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites. Tumor Biol. 2014;35(4):3261–8.
2. Society AC. Cancer facts and figures. Atlanta: American Cancer Society; 2012.
3. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374(9688):477–90.
4. Kim DW, Park SA, Kim CG. Detecting the recurrence of gastric cancer after curative resection: comparison of FDG PET/CT and contrast-enhanced abdominal CT. J Korean Med Sci. 2011;26(7):875–80.
5. Wang J, Yu JC, Kang WM, Ma ZQ. Treatment strategy for early gastric cancer. Surg Oncol. 2012;21(2):119–23.
6. Jay C, Nemunaitis J, Chen P, Fulgham P, Tong AW. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 2007;26(5):293–300.
7. Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther. 2010;12(3):R86.
8. Chen W, Cai F, Zhang B, Barekati Z, Zhang XY. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumor Biol. 2013;34(1):455–62.
9. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuqa T, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010;102(7):1174–9.
10. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 2011;47(5):784–91.
11. Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumor Biol. 2013;34(4):2175–81.
12. Wu W, Takanashi M, Borjigin N, Ohno SI, Fujita K, Hoshino S, et al. MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis. Br J Cancer. 2013;108(3):653–61.
13. Komatsu S, Ichikawa D, Takeshita H, Morimura R, Hirajima S, Tsujiura M, et al. Cirvulating miR-18a: a sensitive cancer screening biomarker in human cancer. In Vivo. 2014;28(3):293–7.
14. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
15. Li C, Li JF, Cai Q, Qiu QQ, Yan M, Liu BY, et al. MiRNA-199a-3p: a potential circulating diagnostic biomarker for early gastric cancer. J Surg Oncol. 2013;108(2):89–92.
16. Gilad S, Meiri E, Yogev Y, Benijamin S, Lebanony D, Yerushalmi N, et al. Serum microRNAs are promising novel biomarkers. PLoS ONE. 2008;3(9):e3148.
17. Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microRNA: a new source of biomarkers. Mutat Res. 2011;717(1–2):85–90.
18. Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang W, et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 2012;316(2):196–203.
19. Wang M, Gu H, Wang S, Qian H, Zhu W, Zhang L, et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol Med Rep. 2012;5(6):1514–20.
20. Woods K, Thomson JM, Hammond SM. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem. 2007;282(4):2130–4.
21. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25(17):2537–45.
22. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis. 2010;11(1):50–4.
23. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26(30):4442–52.
24. Gao W, Shen H, Liu L, Xu J, Shu Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol. 2011;137(4):557–66.
25. Li L, Guo Z, Wang J, Mao Y, Gao Q. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci. 2012;57(11):2910–6.
26. Hirajima S, Komatsu S, Ichikawa D, Takeshita H, Konishi H, Shiozaki A, et al. Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer. 2013;108(9):1822–9.
27. Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, et al. MicroRNA profiling of human gastric cancer. Mol Med Rep. 2009;2(6):963–70.
28. Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, et al. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology. 2009;136(2):683–93.
29. Wu CW, Dong YJ, Liang QY, He XQ, Ng SS, Chan FK, et al. MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer. PLoS ONE. 2013;8(2):e57036.
30. Song L, Lin C, Wu Z, Gong H, Zeng Y, Wu J. miR-18a impairs DNA damage response through downregulation of ataxia telangiectasia mutated (ATM) kinase. PLoS ONE. 2011;6(9). e25454.
31. Tao J, Wu D, Li P, Xue B, Lu Q, Zhang W. microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells. Mol Med Rep. 2012;5(1):167–72.
32. Pinto-Leite R, Carreira I, Melo J, Ferreira SI, Ribeiro I, Ferreira J, et al. Genomic sharacterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer. Tumor Biol. 2014;35(5):4599–617.